RxDoctor Payments Data

Kelli Hanks

Primary Care · Longview, WANPI 1962041996

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $454 of the $534 with a category attached, or 85.0%. 10 manufacturers reported payments, led by Johnson & Johnson at 51.9% of the total.

$534in general payments, 2019–2025

Across 25 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$277
  • UCB, Inc.$40
  • Lilly USA, LLC$38
  • Novartis$38
  • Sanofi$31
  • Paratek Pharmaceuticals, Inc.$31
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$45485%
  • Education$8015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$534 in reported general payments places this provider in the 65th percentile of 94 primary care providers in Washington.

See all primary care providers in Washington

Medicare billing

Part B allowed, 2024
$619
Medicare patients
38
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$137,572
OzempicSemaglutide71$102,622
TradjentaLinagliptin26$35,424
FarxigaDapagliflozin Propanediol31$35,244
XareltoRivaroxaban31$32,161
EliquisApixaban30$28,072
Spiriva HandihalerTiotropium Bromide40$25,139
JanuviaSitagliptin Phosphate15$19,521
TrulicityDulaglutide13$12,879
Combivent RespimatIpratropium/Albuterol Sulfate18$9,141
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,518
Advair HfaFluticasone Propion/Salmeterol18$7,181
SymbicortBudesonide/Formoterol Fumarate26$6,107
Breo ElliptaFluticasone/Vilanterol11$4,867
Gabapentin137$4,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$277$32,16131 claims
Lilly USA, LLCTrulicity, Humalog$38$14,65724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 primary care providers in Washington.

Other primary care in Longview

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →